1
|
Evaluation of DNA Vaccine Candidates against Foot-and-Mouth Disease Virus in Cattle. Vaccines (Basel) 2023; 11:vaccines11020386. [PMID: 36851264 PMCID: PMC9960313 DOI: 10.3390/vaccines11020386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 01/27/2023] [Accepted: 02/03/2023] [Indexed: 02/11/2023] Open
Abstract
We evaluated four DNA vaccine candidates for their ability to produce virus-like particles (VLPs) and elicit a protective immune response against Foot-and-mouth disease virus (FMDV) in cattle. Two traditional DNA plasmids and two DNA minicircle constructs were evaluated. Both the pTarget O1P1-3C plasmid and O1P1-3C minicircle encoded a wild-type FMDV 3C protease to process the P1-2A polypeptide, whereas the O1P1-HIV-3CT minicircle used an HIV-1 ribosomal frameshift to down-regulate expression of a mutant 3C protease. A modified pTarget plasmid with a reduced backbone size, mpTarget O1P1-3CLT, used a 3C protease containing two mutations reported to enhance expression. All constructs produced mature FMDV P1 cleavage products in transfected cells, as seen by western blot analysis. Three constructs, O1P1-3C minicircles, pTarget O1P1-3C, and mpTarget O1P1-3CLT plasmids, produced intracellular VLP crystalline arrays detected by electron microscopy. Despite VLP formation in vitro, none of the DNA vaccine candidates elicited protection from clinical disease when administered independently. Administration of pTarget O1P1-3C plasmid enhanced neutralizing antibody titers when used as a priming dose prior to administration of a conditionally licensed adenovirus-vectored FMD vaccine. Further work is needed to develop these DNA plasmid-based constructs into standalone FMD vaccines in cattle.
Collapse
|
2
|
Effect of Foot-and-Mouth Disease Virus 2B Viroporin on Expression and Extraction of Mammalian Cell Culture Produced Foot-and-Mouth Disease Virus-like Particles. Vaccines (Basel) 2022; 10:vaccines10091506. [PMID: 36146583 PMCID: PMC9502367 DOI: 10.3390/vaccines10091506] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 08/31/2022] [Accepted: 09/07/2022] [Indexed: 12/02/2022] Open
Abstract
To improve the production of foot-and-mouth disease (FMD) molecular vaccines, we sought to understand the effects of the FMD virus (FMDV) 2B viroporin in an experimental, plasmid-based, virus-like particle (VLP) vaccine. Inclusion of the FMDV viroporin 2B into the human Adenovirus 5 vectored FMD vaccine enhanced transgene expression despite independent 2B expression negatively affecting cell viability. Evaluating both wildtype 2B and mutants with disrupted viroporin activity, we confirmed that viroporin activity is detrimental to overall transgene expression when expressed independently. However, the incorporation of 2B into an FMD molecular vaccine construct containing a wildtype FMDV 3C protease, a viral encoded protease responsible for processing structural proteins, resulted in enhancement of transgene expression, validating previous observations. This benefit to transgene expression was negated when using the FMDV 3CL127P mutant, which has reduced processing of host cellular proteins, a reversion resulting from 2B viroporin activity. Inclusion of 2B into VLP production constructs also adversely impacted antigen extraction, a possible side effect of 2B-dependent rearrangement of cellular membranes. These results demonstrate that inclusion of 2B enhanced transgene expression when a wildtype 3C protease is present but was detrimental to transgene expression with the 3CL127P mutant. This has implications for future molecular FMD vaccine constructs, which may utilize mutant FMDV 3C proteases.
Collapse
|
3
|
Puckette M, Primavera V, Martel E, Barrera J, Hurtle W, Clark B, Kamicker B, Zurita M, Brake D, Neilan J. Transiently Transfected Mammalian Cell Cultures: An Adaptable and Effective Platform for Virus-like Particle-Based Vaccines against Foot-and-Mouth Disease Virus. Viruses 2022; 14:v14050989. [PMID: 35632734 PMCID: PMC9147724 DOI: 10.3390/v14050989] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 05/03/2022] [Accepted: 05/05/2022] [Indexed: 01/13/2023] Open
Abstract
RNA viruses, such as foot-and-mouth disease virus (FMDV), have error-prone replication resulting in the continuous emergence of new viral strains capable of evading current vaccine coverage. Vaccine formulations must be regularly updated, which is both costly and technically challenging for many vaccine platforms. In this report, we describe a plasmid-based virus-like particle (VLP) production platform utilizing transiently transfected mammalian cell cultures that combines both the rapid response adaptability of nucleic-acid-based vaccines with the ability to produce intact capsid epitopes required for immunity. Formulated vaccines which employed this platform conferred complete protection from clinical foot-and-mouth disease in both swine and cattle. This novel platform can be quickly adapted to new viral strains and serotypes through targeted exchanges of only the FMDV capsid polypeptide nucleic acid sequences, from which processed structural capsid proteins are derived. This platform obviates the need for high biocontainment manufacturing facilities to produce inactivated whole-virus vaccines from infected mammalian cell cultures, which requires upstream expansion and downstream concentration of large quantities of live virulent viruses.
Collapse
Affiliation(s)
- Michael Puckette
- Plum Island Animal Disease Center, U.S. Department of Homeland Security Science and Technology Directorate, New York, NY 11944, USA; (W.H.); (J.N.)
- Correspondence: ; Tel.: +1-631-323-3176
| | - Victoria Primavera
- Plum Island Animal Disease Center, Leidos, New York, NY 11944, USA; (V.P.); (J.B.); (B.K.); (M.Z.)
- Plum Island Animal Disease Center, SAIC, New York, NY 11944, USA
| | - Erica Martel
- Plum Island Animal Disease Center Research Participation Program, Oak Ridge Institute for Science and Education, New York, NY 11944, USA; (E.M.); (B.C.)
| | - Jose Barrera
- Plum Island Animal Disease Center, Leidos, New York, NY 11944, USA; (V.P.); (J.B.); (B.K.); (M.Z.)
- Plum Island Animal Disease Center, SAIC, New York, NY 11944, USA
| | - William Hurtle
- Plum Island Animal Disease Center, U.S. Department of Homeland Security Science and Technology Directorate, New York, NY 11944, USA; (W.H.); (J.N.)
| | - Benjamin Clark
- Plum Island Animal Disease Center Research Participation Program, Oak Ridge Institute for Science and Education, New York, NY 11944, USA; (E.M.); (B.C.)
| | - Barbara Kamicker
- Plum Island Animal Disease Center, Leidos, New York, NY 11944, USA; (V.P.); (J.B.); (B.K.); (M.Z.)
- Plum Island Animal Disease Center, SAIC, New York, NY 11944, USA
| | - Mariceny Zurita
- Plum Island Animal Disease Center, Leidos, New York, NY 11944, USA; (V.P.); (J.B.); (B.K.); (M.Z.)
- Plum Island Animal Disease Center, SAIC, New York, NY 11944, USA
| | - David Brake
- BioQuest Associates, LLC, P.O. Box 787, Stowe, VT 05672, USA;
| | - John Neilan
- Plum Island Animal Disease Center, U.S. Department of Homeland Security Science and Technology Directorate, New York, NY 11944, USA; (W.H.); (J.N.)
| |
Collapse
|